David R DAdamo
Overview
Explore the profile of David R DAdamo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tolaney S, Kalinsky K, Kaklamani V, DAdamo D, Aktan G, Tsai M, et al.
Clin Cancer Res
. 2021 Mar;
27(11):3061-3068.
PMID: 33727258
Purpose: As monotherapies, eribulin (chemotherapy) and pembrolizumab (immunotherapy) have shown promise for patients with metastatic triple-negative breast cancer (mTNBC). This phase Ib/II study examined eribulin plus pembrolizumab as a potential...
2.
Blay J, Schoffski P, Bauer S, Krarup-Hansen A, Benson C, DAdamo D, et al.
Br J Cancer
. 2019 May;
120(11):1026-1032.
PMID: 31065111
Background: This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma. Methods: Patients ≥18 years old with advanced liposarcoma or leiomyosarcoma, ECOG...
3.
DAdamo D, Dickson M, Keohan M, Carvajal R, Hensley M, Hirst C, et al.
Oncologist
. 2018 Aug;
24(6):857-863.
PMID: 30126857
Background: Sorafenib and dacarbazine have low single-agent response rates in metastatic sarcomas. As angiogenesis inhibitors can enhance the efficacy of chemotherapy, we investigated the combination of sorafenib and dacarbazine in...
4.
LaVigne A, Meredith D, DAdamo D, Margalit D
BMJ Case Rep
. 2018 Apr;
2018.
PMID: 29643133
We present a challenging case of a previously healthy 23-year-old man who developed an inflammatory myofibroblastic tumour of the hard palate, harbouring a rearrangement of the anaplastic lymphoma kinase (ALK)...
5.
Demetri G, Schoffski P, Grignani G, Blay J, Maki R, Van Tine B, et al.
J Clin Oncol
. 2017 Aug;
35(30):3433-3439.
PMID: 28854066
Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement in overall survival (OS) for the eribulin arm, with...
6.
Dickson M, DAdamo D, Keohan M, DAngelo S, Carvajal R, Gounder M, et al.
Sarcoma
. 2015 Jun;
2015:532478.
PMID: 26074722
Gemcitabine (G) and docetaxel (D) are commonly used to treat recurrent/metastatic soft tissue sarcoma. This study tested the hypothesis that outcomes would be improved by addition of bevacizumab (B). The...
7.
Maki R, Jungbluth A, Gnjatic S, Schwartz G, DAdamo D, Keohan M, et al.
Sarcoma
. 2013 Apr;
2013:168145.
PMID: 23554566
Background. Patients with recurrent synovial sarcomas have few options for systemic therapy. Since they express large amounts of endogenous CT (cancer testis) antigens such as NY-ESO-1, we investigated the clinical...
8.
Luke J, DAdamo D, Dickson M, Keohan M, Carvajal R, Maki R, et al.
Clin Cancer Res
. 2012 Mar;
18(9):2638-47.
PMID: 22374332
Purpose: Dysregulated cyclin-dependent kinases are important to the growth of some sarcomas. Flavopiridol is a pan-CDK inhibitor that has been shown to potentiate chemotherapy. As such, we explored the potentiation...
9.
DAdamo D
Semin Oncol
. 2011 Nov;
38 Suppl 3:S19-29.
PMID: 22055968
Sarcomas are a heterogeneous group of relatively rare mesenchymal neoplasms. They can be grouped into two general categories: soft tissue sarcoma (STS) and primary bone sarcoma, which are treated differently....
10.